A Study to Assess the pharmacoMRI Effects of AUT00206 in Healthy Males

Ketamine

Brief Summary

A Phase 1, Single-centre, Double-blind, Placebo controlled Crossover Study to Assess the pharmacoMRI Effects of AUT00206 in Healthy Male Participants

Intervention / Treatment

  • Drug: Low dose AUT00206 800mg
  • Drug: High dose AUT00206 2000 mg
  • Drug: Placebo
  • Drug: Ketamine
  • Other: Saline

Condition or Disease

  • Schizophrenia

Phase

Study Design

Study type: Interventional
Status: Completed
Study results: No Results Available
Age: 18 Years to 45 Years   (Adult)
Enrollment: 22 ()
Funded by: Industry|Other

Masking

Clinical Trial Dates

Start date: Oct 16, 2020
Primary Completion: Nov 17, 2020
Completion Date: Nov 17, 2020
Study First Posted: Oct 17, 2016
Results First Posted: Aug 31, 2020
Last Updated: Nov 27, 2017

Sponsors / Collaborators

Lead Sponsor: N/A
Responsible Party: N/A

Location

London, England, United Kingdom

Eligibility Criteria

Sex: Male
Minimum Age: 18
Maximum Age: 45

More Details

NCT Number: NCT02935725
Other IDs: AUT021206|2016-000216-14
Study URL: https://ClinicalTrials.gov/show/NCT02935725
Last updated: Jan 27, 2021